Cyxone announced the recruitment of Erika Samuelsson as the new Chief Development Officer with responsibility for clinical and non-clinical activities with Cyxone's drug candidates.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.105 SEK | -4.55% |
|
-11.02% | +4.58% |
05-14 | Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-22 | Sweden's Cyxone Appoints New CEO | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.58% | 2.24M | |
+16.96% | 9.05B | |
-21.41% | 4.4B | |
+21.80% | 4.39B | |
+27.00% | 3.94B | |
+3.80% | 2.1B | |
+12.87% | 1.97B | |
-34.72% | 1.87B | |
-0.50% | 1.64B | |
-43.28% | 1.61B |
- Stock Market
- Equities
- CYXO Stock
- News Cyxone AB
- Cyxone Appoints Erika Samuelsson as Chief Development Officer